Beta-CIT-SPECT and Neurophysiology in Depression

Serotonin and Dopamine Transporter (SERT, DAT) Availabilities as Assessed by b-CIT and SPECT, and Neurophysiological Measures of Central Serotonergic Activity in Patients With Depression Under Treatment With Escitalopram

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00145132

Enrollment

Registered

2005-09-05

Start date

2005-06-30

Completion date

2009-12-31

Last updated

2010-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

depression, β-CIT-SPECT, SERT, DAT, neurophysiology, LDAEP, escitalopram, SSRI

Brief summary

Aim of this project is to investigate the effects of escitalopram on monoamine transporter (SERT, DAT) availabilities as assessed by b-CIT and SPECT, and on neurophysiological parameters such as the loudness dependence of auditory evoked potentials (LDAEP) in patients with depression.

Interventions

PROCEDUREβ-CIT-SPECT, Neurophysiology

β-CIT-SPECT scans and EEG recordings, two assessments each

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Psychiatric in or outpatients with acute depressive episode * Indication for pharmacological treatment

Exclusion criteria

* Acute suicidality * Neurological or severe somatic disorders * Occupational exposition to radiation \>15 mSv per year * Women during pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
changes in β-CIT/neurophysiological measurements from baseline to week 4	two assessments, at baseline and week 4

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026